Elanco Animal Health Incorporated
NYSE:ELAN · New York Stock Exchange
-$0.84 today
Vol 4.26M · Avg 6.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-3.5%
avg -3.1%
ROIC
2.1%
avg 2.0%
ROA
-1.7%
avg -1.5%
Analysis
ROIC is currently the strongest return metric at 2.1% versus its period average of 2.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jeffrey N. Simmons | President, Chief Executive Officer & Director | $2.93M | — | 59 | $24,541.95 | <0.01% |
Robert VanHimbergen | Executive Vice President & Chief Financial Officer | $1.83M | — | 50 | $100.83 | <0.01% |
Ellen de Brabander | Executive Vice President of Research, Development & Regulatory Affairs | $1.62M | — | 63 | $301,109.00 | 0.06% |
Ramiro Martin Cabral | Executive Vice President & President of Elanco International | $1.24M | — | 54 | $283,874.00 | 0.06% |
Timothy J. Bettington | Executive Vice President of Center of Strategic Growth | $1.18M | — | 52 | $143,261.00 | 0.03% |
David S. Kinard | Executive Vice President of Human Resources, Corporate Communications & Administration | $722,576.00 | — | 59 | $111,451.00 | 0.02% |
James Meer | Senior Vice President & Chief Accounting Officer | — | — | 56 | $66,732.00 | 0.01% |
Larbi Van Lier | Senior Vice President of Asia | — | — | — | — | — |
Shiv O'Neill | Executive Vice President, General Counsel & Corporate Secretary | — | — | 51 | $83,834.00 | 0.02% |
Tiffany Ann Kanaga | Vice President of Investor Relations & ESG | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$1.14M
Sells
0
$0.00
Net Sentiment
+$1.14M
Net buying
Most Active
Modi Rajeev A.
2 transactions
Analysis
Insiders reported 6 buys worth $1.14M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.14M. Modi Rajeev A. was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +21.5% (11yr)2 analysts |
| Revenue | N/A | N/A | +1.8% | +6.3% (11yr)5 analysts |
| Net Income | N/A | N/A | N/A | +24.6% (11yr)5 analysts |
| EBIT | N/A | N/A | +9.3% | N/A5 analysts |
Analysis
Recent growth has been strongest in EBIT at +9.3% over three years. Forward estimates point to Net Income at +24.6% (11yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$33.54B
Viatris Inc.
NASDAQ:VTRS
$18.32B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$15.99B
Solventum Corporation
NYSE:SOLV
$12.91B
Align Technology, Inc.
NASDAQ:ALGN
$12.43B
Dr. Reddy's Laboratories Limited
NYSE:RDY
$10.95B
Revvity, Inc.
NYSE:RVTY
$10.91B
Encompass Health Corporation
NYSE:EHC
$9.71B
The Ensign Group, Inc.
NASDAQ:ENSG
$9.11B
Qiagen N.V.
NYSE:QGEN
$7.54B
Who manages ELAN?
Elanco Animal Health Incorporated (ELAN) lists 10 active executives. The top listed executive is Timothy J. Bettington, Executive Vice President of Center of Strategic Growth.
Are ELAN insiders buying or selling?
Recent insider activity shows net buying of $11.81M.
Explore More
Continue the stock analysis
Jump to another research area for this company.